Streetbeat News

Products Services

DQ

Daqo New Energy reported a Q1 polysilicon production volume of 62,278MT, an increase from 61,014MT in Q4 FY23. However, polysilicon sales volume decreased to 53,987MT from 59,906MT in the same period.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 10:40 am

CMPS

Compass Pathways and Journey Clinical have partnered to develop a scalable and practical delivery and healthcare provider training model for COMP360 psilocybin treatment, aimed at treating resistant depression if approved.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 10:38 am

XFOR

X4 Pharmaceuticals' stock is trading higher following the FDA's approval of Xolremdi (mavorixafor) for the treatment of WHIM syndrome.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 10:34 am

XFOR

The FDA has approved X4 Pharmaceuticals' Xolremdi (Mavorixafor) capsules for patients 12 years and older with WHIM Syndrome, aimed at increasing circulating mature neutrophils and lymphocytes.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 10:32 am

TSLA

Elon Musk's recent visit to China for Tesla's FSD push coincides with China's increasing focus on hydrogen-powered vehicles as an alternative for green energy transition. The Chinese government is rolling out incentives for hydrogen vehicles, with Sichuan province leading initiatives like toll exemptions and subsidies for hydrogen refueling stations. Meanwhile, China's EV sector faces overcapacity, with production outpacing sales. Despite Musk's skepticism towards hydrogen energy, China is advancing its hydrogen infrastructure, positioning itself as a leader in clean energy. Tesla is also partnering with Baidu to introduce driver assistance features in China.

Portfolio Pulse from Pooja Rajkumari

April 29, 2024 | 10:32 am

MNKD

MannKind Corporation announced that the U.S. FDA has cleared its IND application for MNKD-101, a Clofazimine Inhalation Suspension, to start a Phase 3 study for treating nontuberculous mycobacterial lung disease. This marks a significant step in the development and commercialization of innovative inhaled therapeutic products targeting endocrine and orphan lung diseases.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 10:07 am

BMY

Bristol Myers Squibb (NYSE:BMY) and Repertoire Immune Medicines have announced a strategic collaboration worth up to $1.8 billion to develop tolerizing vaccines for autoimmune diseases. Repertoire will receive an upfront payment of $65 million, with potential for additional milestone payments and tiered royalties.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 10:03 am

TSLA

Tesla Inc (NASDAQ:TSLA) is planning a European tour for its Cybertruck, starting April 30, covering cities like London, Berlin, and Amsterdam, despite the vehicle not being for sale in Europe. This follows a similar tour in China earlier this year. Tesla aims to deliver 250,000 units annually by 2025 but faced a recall of 3,878 vehicles over unintended acceleration issues.

Portfolio Pulse from Anan Ashraf

April 29, 2024 | 9:17 am

WTW

WTW (NASDAQ:WTW) has partnered with Riskonnect to launch a new analytical tool, WTW Risk IQ API, aimed at enhancing the evaluation of claims and exposure data. This collaboration seeks to streamline the process of analyzing risk and claims data, reducing errors and inefficiencies by eliminating manual data entry, thereby providing clients with actionable insights for risk mitigation.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 9:01 am

PSFE

Paysafe (NYSE:PSFE) has launched Pay by Bank for iGaming, a solution enabling U.S. online bettors to fund deposits and cash out winnings directly from their online bank accounts. This expands Paysafe's Gateway, enhancing its iGaming payments solution by connecting U.S. operators to a wide range of payment methods through a single integration.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 8:04 am